<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113334</url>
  </required_header>
  <id_info>
    <org_study_id>2003-1027</org_study_id>
    <nct_id>NCT00113334</nct_id>
  </id_info>
  <brief_title>Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer</brief_title>
  <official_title>A Phase 1b/2 Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this clinical research study are to see how individuals with advanced head and&#xD;
      neck cancer respond to treatment with the new drug thrombospondin (ABT-510) and to learn how&#xD;
      effective it is in destroying cancer cells. The safety of ABT-510 and the effect ABT-510 has&#xD;
      on cells in the body will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase Ib/II, single-center, open-label study designed to assess the safety,&#xD;
      tolerability, pharmacokinetics, and biologic efficacy of ABT-510 (thrombospondin).&#xD;
      Participants will be patients with incurable head and neck cancer.&#xD;
&#xD;
      Patients will begin at a fixed dose level of thrombospondin subcutaneously twice daily.&#xD;
      Cycles of treatment are 28 days (4 weeks). Patients will be treated with thrombospondin until&#xD;
      progression of tumor or toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Baseline to 6 weeks for PR or CR response assessment (minimal 4 week cycle + assessments). Overall study period 3 years.</time_frame>
    <description>Response rate defined as percentage of number of complete response or partial response in total number of participants treated. Response Evaluation Criteria in Solid Tumors (RECIST): Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): &gt;20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1/&gt; new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD. Trial conducted by Simon's optimal two-stage design and response rate estimated accordingly. For status of PR or CR, changes in tumor measurements confirmed by repeat assessments performed at 6 weeks, no less than 4 weeks after criteria for response is first met.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>ABT-510 (Thrombospondin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-510</intervention_name>
    <description>100 mg subcutaneously twice daily</description>
    <arm_group_label>ABT-510 (Thrombospondin)</arm_group_label>
    <other_name>Thrombospondin Analogue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has histologically proven squamous cell carcinoma of the head and neck that is&#xD;
             not amenable to curative therapy, including radiation or surgery (including surgery&#xD;
             following induction chemotherapy or chemo-radiation).&#xD;
&#xD;
          -  Patient's tumor is biopsy accessible.&#xD;
&#xD;
          -  Patient has a Karnofsky performance status &gt;/= 70.&#xD;
&#xD;
          -  Patient has adequate bone marrow function: White blood count (WBC) &gt;/= 3,000&#xD;
             cells/mm3, absolute neutrophil count (ANC) &gt;/= 1,500 cells/mm3, platelet count &gt;/=&#xD;
             100,000 cells/mm3, Hgb &gt;/= 9.0 g/dL.&#xD;
&#xD;
          -  Patient has adequate liver function: total bilirubin level &lt;/= 2.0 mg/dL, albumin &gt;/=&#xD;
             2.5 g/dL.&#xD;
&#xD;
          -  Transaminases (SGOT and/or SGPT) may be up to 2.5 * upper limit of normal (ULN) if&#xD;
             alkaline phosphatase is &lt;/= ULN, or alkaline phosphatase may be up to 4 x ULN if&#xD;
             transaminases are &lt;/= ULN. However, patients who have both transaminase elevation &gt;&#xD;
             1.5 * ULN and alkaline phosphatase &gt; 2.5 * ULN are not eligible for this study.&#xD;
&#xD;
          -  Patient has serum creatinine &lt; 2 mg/dl&#xD;
&#xD;
          -  Patient has signed a written informed consent.&#xD;
&#xD;
          -  Patient may have received any number of prior chemotherapeutic regimens for recurrent&#xD;
             or metastatic disease.&#xD;
&#xD;
          -  The subject must not be pregnant or breastfeeding. All subjects (male and female)&#xD;
             should practice contraception (e.g., barrier, hormonal, intrauterine device [IUD]) or&#xD;
             abstain from sexual intercourse while in the study and for up to two months following&#xD;
             completion of therapy.&#xD;
&#xD;
          -  The subject is able to self-administer or has a caregiver who can reliably administer&#xD;
             subcutaneous (SC) injections.&#xD;
&#xD;
          -  Patient &gt;/= 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No biopsy accessible tissue.&#xD;
&#xD;
          -  Patient has received prior radiation therapy to biopsy site within the past 3 months.&#xD;
             (Patient may have received palliative radiation within the past 2 weeks, but not to&#xD;
             the biopsy site.)&#xD;
&#xD;
          -  Patient exhibits confusion, disorientation, or has a history of major psychiatric&#xD;
             illness which may impair patient's understanding of the informed consent.&#xD;
&#xD;
          -  Patient requires total parenteral nutrition with lipids.&#xD;
&#xD;
          -  Patient has a history of uncontrolled heart disease including congestive heart&#xD;
             failure, angina at rest, myocardial infarct in the last 6 months, uncontrolled&#xD;
             hypertension with systolic blood pressure (BP) &gt;160 or diastolic BP &gt;90, systolic&#xD;
             blood pressure (BP) &lt;90 or symptomatic hypotension, or symptomatic or potentially&#xD;
             life-threatening tachycardia, bradycardia or arrhythmia.&#xD;
&#xD;
          -  Pregnant women and women who are currently breast-feeding may not participate in this&#xD;
             study. All women of childbearing potential must have a negative pregnancy test within&#xD;
             24 hours prior to enrolling in the study.&#xD;
&#xD;
          -  Serious infection or other intercurrent illness requiring immediate therapy.&#xD;
&#xD;
          -  The subject has a history of or currently exhibits clinically significant cancer&#xD;
             related events of bleeding (e.g., hemoptysis). The subject has a recent history of&#xD;
             (within 4 weeks from Study Day 1) or currently exhibits other clinically significant&#xD;
             events of bleeding.&#xD;
&#xD;
          -  If subject is receiving therapeutic anticoagulation therapy, low dose anticoagulation&#xD;
             for catheter prophylaxis will be permitted; PT/PTT must be within normal limits.&#xD;
&#xD;
          -  The patient has a history of or currently exhibits central nervous system (CNS)&#xD;
             metastasis. Brain magnetic resonance imaging (MRI) within 28 days of enrollment is&#xD;
             required to confirm the absence of CNS metastases.&#xD;
&#xD;
          -  Patient has received chemotherapy or biologic therapy within 3 weeks of registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward S. Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 7, 2005</study_first_submitted>
  <study_first_submitted_qc>June 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2005</study_first_posted>
  <results_first_submitted>April 24, 2009</results_first_submitted>
  <results_first_submitted_qc>April 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2009</results_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Thrombospondin Analogue</keyword>
  <keyword>ABT-510</keyword>
  <keyword>Antiangiogenic agent</keyword>
  <keyword>Lung</keyword>
  <keyword>Skin</keyword>
  <keyword>Thyroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 06/10/05 through 03/02/07. All participants recruited at University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ABT-510 (Thrombospondin)</title>
          <description>Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABT-510 (Thrombospondin)</title>
          <description>Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="43" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Response rate defined as percentage of number of complete response or partial response in total number of participants treated. Response Evaluation Criteria in Solid Tumors (RECIST): Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): &gt;20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1/&gt; new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD. Trial conducted by Simon's optimal two-stage design and response rate estimated accordingly. For status of PR or CR, changes in tumor measurements confirmed by repeat assessments performed at 6 weeks, no less than 4 weeks after criteria for response is first met.</description>
        <time_frame>Baseline to 6 weeks for PR or CR response assessment (minimal 4 week cycle + assessments). Overall study period 3 years.</time_frame>
        <population>Three (3) patients were inevaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-510 (Thrombospondin)</title>
            <description>Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response rate defined as percentage of number of complete response or partial response in total number of participants treated. Response Evaluation Criteria in Solid Tumors (RECIST): Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): &gt;30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): &gt;20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1/&gt; new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD. Trial conducted by Simon's optimal two-stage design and response rate estimated accordingly. For status of PR or CR, changes in tumor measurements confirmed by repeat assessments performed at 6 weeks, no less than 4 weeks after criteria for response is first met.</description>
          <population>Three (3) patients were inevaluable for response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Change/Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks, minimally 28 days for treatment cycle (4 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ABT-510 (Thrombospondin)</title>
          <description>Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Kim, MD, BS / Assistant Professor</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-6363</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

